FDA approves ‘precision medicine’ drug for different cancers with same mutation
The Food and Drug Administration on Monday approved a drug for a wide range of cancers based on a shared mutation, rather than the tumors’ locations — an advance for the sometimes controversial field of “precision medicine.”
